Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Vicagrel is the acetated form of Clopidogrel with antithrombotic activity. It treats thrombosis by acting as a P2Y12 platelet inhibitor. Vicagrel had antiplatelet potency that was significantly higher than clopidogrel and comparable to prasugrel. According to preliminary pharmacokinetic study results, clopidogrel thiolactone generated from vicagrel had a 6-fold higher bioavailability than clopidogrel, suggesting a much lower clinically effective dose for vicagrel when compared to clopidogrel. Overall, vicagrel is a more promising and safer antiplatelet agent than clopidogrel, with potential benefits that include: (1) no drug resistance for CYP2C19 poor metabolizers; (2) lower dose-related toxicity because of a much lower effective dose; and (3) a faster onset of action.
ln Vitro |
Vicagrel (compound 9a) (20 μM, 30 min) stimulates the in vitro rat liver microsomal production of the active metabolite[1].
|
---|---|
ln Vivo |
Vicagrel (compound 9a) (oral, 3 mg/kg) inhibits the aggregation of platelets in rats induced by ADP[1].
Vicagrel (orally, 1.14 mg/mL, 0–24 h) has a low clinically effective dose, good bioavailability, and good preliminary pharmacokinetics[1]. Vicagrel (oral, 5 g/kg, single, for 14 days) exhibits minimal dose-related toxicity in mouse[1]. |
Animal Protocol |
Male Wistar rats, (200−250 g)
3 mg/kg oral |
References |
Molecular Formula |
C18H18CLNO4S
|
|
---|---|---|
Molecular Weight |
379.86
|
|
Exact Mass |
379.06
|
|
Elemental Analysis |
C, 56.92; H, 4.78; Cl, 9.33; N, 3.69; O, 16.85; S, 8.44
|
|
CAS # |
1314081-53-2
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
CC(=O)OC1=CC2=C(S1)CCN(C2)[C@@H](C3=CC=CC=C3Cl)C(=O)OC
|
|
InChi Key |
GNHHCBSBCDGWND-KRWDZBQOSA-N
|
|
InChi Code |
InChI=1S/C18H18ClNO4S/c1-11(21)24-16-9-12-10-20(8-7-15(12)25-16)17(18(22)23-2)13-5-3-4-6-14(13)19/h3-6,9,17H,7-8,10H2,1-2H3/t17-/m0/s1
|
|
Chemical Name |
methyl (2S)-2-(2-acetyloxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-2-(2-chlorophenyl)acetate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6325 mL | 13.1627 mL | 26.3255 mL | |
5 mM | 0.5265 mL | 2.6325 mL | 5.2651 mL | |
10 mM | 0.2633 mL | 1.3163 mL | 2.6325 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05651074 | Recruiting | Drug: Vicagrel and omeprazole | Healthy Subjects | Jiangsu vcare pharmaceutical technology co., LTD |
November 14, 2022 | Phase 1 |
NCT04143750 | Completed | Drug: [14C]Vicagrel | Healthy Male Adult | Jiangsu vcare pharmaceutical technology co., LTD |
November 11, 2019 | Phase 1 |
NCT05162053 | Completed | Drug: vicagrel Capsules Drug: Clopidogrel Tablets |
Acute Coronary Syndrome | Jiangsu vcare pharmaceutical technology co., LTD |
December 9, 2021 | Phase 1 |
NCT04919551 | Completed | Drug: vicagrel | Acute Coronary Syndrome | Jiangsu vcare pharmaceutical technology co., LTD |
August 24, 2021 | Phase 1 |
NCT03599284 | Completed | Drug: Vicagrel 5mg Drug: Vicagrel 6mg |
Coronary Artery Disease Platelet Aggregation Inhibitors |
Jiangsu vcare pharmaceutical technology co., LTD |
August 30, 2018 | Phase 2 |
J Med Chem.2012 Apr 12;55(7):3342-52. th> |
---|